The local hypothalamic–pituitary–adrenal axis in cultured human dermal papilla cells

Eun Young Lee  
CHA University

You Jin Nam  
CHA University  https://orcid.org/0000-0002-6603-5586

Sangjin Kang  
CHA University

Eun Ju Choi  
CHA University

Inbo Han  
CHA Bundang Medical Center

Jinwan Kim  
Chabio F&C

Dong Hyun Kim  
CHA Bundang Medical Center

Ji Hae An  
CHA Bundang Medical Center

Sunghou Lee  
Sangmyung University

Min Ho Lee  
GF HERB

Ji Hyung Chung  (jhchung@cha.ac.kr)  
https://orcid.org/0000-0003-0731-1349

Research article

Keywords: Corticotropin releasing factor, hair loss, human dermal papilla cells, human hair follicle, stress hormone

Posted Date: January 17th, 2020

DOI: https://doi.org/10.21203/rs.2.21076/v1

License: ☐ ☑ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
**Version of Record:** A version of this preprint was published at BMC Molecular and Cell Biology on June 10th, 2020. See the published version at [https://doi.org/10.1186/s12860-020-00287-w](https://doi.org/10.1186/s12860-020-00287-w).
Abstract

Background: Stress is an important cause of skin disease, including hair loss. The hormonal response to stress is due to the HPA axis, which comprises hormones such as corticotropin releasing factor (CRF), adrenocorticotropic hormone (ACTH), and cortisol. Many reports have shown that CRF, a crucial stress hormone, inhibits hair growth and induces hair loss. However, the underlying mechanisms are still unclear. The aim of this study was to examine the effect of CRF on human dermal papilla cells (DPCs) as well as hair follicles and to investigate whether the HPA axis was established in cultured human DPCs.

Results: CRF inhibited hair shaft elongation and induced early catagen transition in human hair follicles. Hair follicle cells, both human DPCs and human ORSCs, expressed CRF and its receptors and responded to CRF. CRF inhibited the proliferation of human DPCs through cell cycle arrest at G2/M phase and induced the accumulation of reactive oxygen species (ROS). Anagen-related cytokine levels were downregulated in CRF-treated human DPCs. Interestingly, increases in proopiomelanocortin (POMC), ACTH, and cortisol were induced by CRF in human DPCs, and antagonists for the CRF receptor blocked the effects of this hormone.

Conclusion: The results of this study showed that stress can cause hair loss by acting through stress hormones. Additionally, these results suggested that a fully functional HPA axis exists in human DPCs and that CRF directly affects human DPCs as well as human hair follicles under stress conditions.

Background

Hair follicles (HFs) consist of mesenchymal-derived dermal papilla cells (DPCs) and epithelial-derived root sheath cells, and the interaction between mesenchymal and epithelial tissues regulates hair development and the hair cycle (1, 2). The hair cycle is divided into anagen, catagen, and telogen according to the morphology of the HFs. These cycles can be explained in terms of the growth phase, regression phase, and rest phase (3). In addition, DPCs produce and secrete various cytokines that control hair development and the hair cycle (4). Indeed, many researchers have used DPCs to study hair loss.

The hypothalamic–pituitary–adrenal axis (HPA axis) is a classical system response that plays a role in maintaining stress-related homeostasis. This essential response is activated by various factors, including physical, emotional, and neurological stresses (5). Corticotropin releasing factor (CRF), adrenocorticotropic hormone (ACTH), and glucocorticoids are crucial stress-related hormones of the HPA axis (6). Stress stimulates CRF production in the hypothalamus. After activation through the CRF receptor (CRFR), the anterior pituitary produces proopiomelanocortin (POMC)-derived ACTH, which produces cortisol (human) or glucocorticoids (rodent) as the main end effectors of the HPA axis in the adrenal cortex (7–10). Cortisol acts as a negative feedback system to suppress the release of CRF. Thus, the hormone levels in the blood are maintained at a constant level (11).

CRF, composed of 41 amino acids, is the main trigger of the HPA axis and also plays an important role in the stress response of vertebrates. Activation of adenylyl cyclase and upregulation of cyclic AMP levels
occur when CRF interacts with CRFR1 or CRFR2, membrane receptors of the class B subtype of G protein coupled receptors (GPCRs), in response to these receptors (12, 13). As a result, protein kinase A (PKA) and cAMP response element binding protein (CREB) phosphorylate downstream targets in the cytoplasm and nucleus, respectively (14).

The human skin is the largest organ and has abundant HFs, except on the palms, soles, and nails (1). There are many reports of cutaneous HPA axis homologues in the skin (6). Skin expresses all elements of the HPA axis, including CRF, POMC, ACTH, and β-endorphin, with the corresponding receptors (9, 15). These results indicate that these molecules play a role in the skin. A previous study showed that human HFs have their own peripheral HPA axis. Additionally, human HFs secrete stress-related hormones, including CRF, ACTH, and glucocorticoids. The human hair bulb is the target of CRF as well (16). Moreover, CRF inhibited hair growth and induced apoptosis of hair matrix keratinocytes in cultured human HFs (17, 18). Interestingly, hair regrowth was observed in a CRF-overexpressing mouse model after treatment with a CRF receptor antagonist (19).

Recently, studies have specifically examined the interactions among stress hormones, the neuroendocrine system and skin diseases, such as hair loss (20–24). Stress changes the hair cycle and induces hair loss. However, the underlying biochemical mechanisms of stress-induced hair loss are still unclear.

The aims of this study were to determine the CRF-induced modulations in human DPCs that have a major role HFs and investigate whether the local HPA axis is functional in DPCs. Through these analyses, we will elucidate the mechanism of stress-induced hair loss.

**Results**

CRF, a stress hormone, inhibited hair shaft elongation and induced early catagen transition in human HF organ culture.

To confirm the deleterious effects of CRF on HFs, we exposed anagen-phase human HFs to CRF, and hair shaft elongation and hair cycle transition were monitored. CRF significantly suppressed hair shaft elongation. The hair shaft was decreased by approximately 30% in the CRF treatment group compared with that in the negative control group at 2, 5, and 10 days (Fig. 1A).

The hair cycle score is an arbitrary grading method based on the morphological characteristics of each HF. Anagen VI HFs were ascribed an arbitrary value of 100, early catagen HFs were given a score of 200, mid-catagen HFs were given a score of 300, and late catagen HFs were given a score of 400; these values were used to calculate the hair cycle score. The hair cycle score was significantly higher in the CRF-treated group (235 ± 25.4 and 360 ± 18.4) than in the control group (145 ± 18.5 and 260 ± 32.8) at 3 and 6 days, respectively, indicating that CRF induced premature catagen transition (Fig. 1B).

Human DPCs express CRF receptors and respond to CRF.
To determine whether CRF can affect the number of cells comprising the HFs, we analyzed the expression of CRF receptors in cultured human DPCs and outer root sheath cells (ORSCs). Endogenous expression of CRF and CRF receptors was detected by the immunocytochemistry method in both human DPCs and ORSCs (Fig. 2A, B). Interestingly, fluorescence intensity was increased in human DPCs after exposure to $10^{-6}$ M CRF for 24 hours (Fig. 2C). Increased expression of CRF and its receptors was confirmed by western blot analysis. Both CRFR1 and CRFR2, as well as CRF, were endogenously expressed and increased by CRF treatment in human DPCs (Fig. 2D, E, F, G).

CRF inhibited proliferation through cell cycle arrest in cultured human DPCs.

For selection of the experimental CRF concentration, we exposed human DPCs to various concentrations of CRF, and the cells were quantified after 2 days. A significant difference was observed in total cells between the CRF group (at a concentration of $10^{-6}$ M) and the control group, and this change was reversed by antagonists of the CRF receptor (Fig. 3A, B).

To determine whether the changes in the CRF treatment group were caused by cell death or by inhibition of cell proliferation, we exposed cells to $10^{-6}$ M CRF for 48 hours and stained them with Annexin V FITC and PI. In the untreated control sample, the majority (97.03%) of the cells were viable and nonapoptotic, and the CRF-treated cells showed no change in viability (97.33%) (Fig. 3C). This result suggests that CRF did not influence cell survival or apoptosis but inhibited cell proliferation.

To further determine how CRF suppressed the proliferation of human DPCs, we performed FACs analysis of the cell cycle. Compared with the negative control treatment, treatment with $10^{-6}$ M CRF resulted in a 7.2% increase in the S phase cells at 24 hours. Ultimately, CRF resulted in 21.2% and 25.5% increases in the G2/M phase cells at 48 hours and 72 hours, respectively. Interestingly, we did not observe any apoptotic cells (sub-G1 fraction) up to 72 hours after the CRF treatment (Fig. 3D, E).

Because accumulation of ROS was implicated in cell cycle arrest (25), the ROS levels were monitored in CRF-treated cells by DCFDA fluorescence analysis. CRF increased the fluorescence signal by approximately 30% compared to that of the control group (Fig. 3F). Additionally, antalarmin and astressin 2-B normalized the DCF fluorescence levels. These data indicated that CRF induced ROS in cultured human DPCs.

The expression levels of anagen-related cytokines were downregulated by CRF in cultured human DPCs.

RT-PCR and western blot analyses of cultured human DPCs were performed to determine whether CRF affects cytokines, which are typically produced and released by DPCs during the anagen phase. CRF significantly changed the mRNA levels of HGF, Wnt5a, TGFβ2, VEGF, and versican, but the CRFR1 antagonist antalarmin significantly affected only HGF (Fig. 4A, B). The protein levels of these cytokines, including HGF, Wnt5a, TGFβ2, and versican, were also modulated by CRF treatment and were effectively restored with antalarmin or astressin 2-B pretreatment (Fig. 4C, D).
The local HPA axis in cultured human DPCs.

To confirm the downstream events following CRF-receptor binding, we monitored the levels of a second messenger, cAMP, after CRF treatment. Following CRF treatment, the cAMP level was approximately two times (5.51 ± 0.05 pmol/ml/µg/µl) that of the control (2.97 ± 0.06 pmol/ml/µg/µl). Additionally, the cAMP levels were significantly decreased by antalarmin (5.03 ± 0.03 pmol/ml/ug/ul) and astressin 2-B (4.11 ± 0.03 pmol/ml/µg/µl). Therefore, we confirmed that the CRF effects occurred inside human DPCs (Fig. 5A).

To determine whether the HPA axis was fully functional in cultured human DPCs, we administered antagonists to cells incubated with 10⁻⁶ M CRF and analyzed the expression levels of POMC, ACTH, and cortisol. The mRNA and protein levels of POMC were upregulated by CRF treatment (Fig. 5B, C). In particular, the protein level increased almost 2.5-fold. The increased POMC protein was significantly downregulated by both antalarmin and astressin 2-B treatment (Fig. 5C, D). In addition to these changes, the secretion of ACTH was stimulated by CRF (2.7-fold) in cultured human DPCs. Antalarmin significantly recovered the ACTH concentration, but astressin 2-B showed a tendency to decrease ACTH, and the effect was not significant (Fig. 5E). Furthermore, CRF slightly increased the cortisol level (1.28-fold) in cultured human DPCs (Fig. 5F). The increased cortisol level, though not significant, was reduced by antalarmin and astressin 2-B treatment. Overall, these findings indicate that cultured human DPCs have a complete local HPA axis.

**Discussion**

Recently, hair loss has increased in women and young people. This hair loss is believed to be caused by various stressors rather than by genetic factors. Thus, the accumulation of data on the effects of stress on HFs and their constituent cells is important for treatment of hair loss (8, 26, 27). However, knowledge of the relationship between stress hormones and hair loss is limited. In particular, CRF is an important hormone of the HPA axis in the peripheral stress response. While several reports have identified the role of stress hormones such as CRF, ACTH, and cortisol in hair loss in in vivo models or human HF organ culture, the exact cellular mechanisms have not been studied (16, 19, 28).

In this study, CRF stimulation significantly inhibited hair shaft elongation and induced the early catagen transition of human HFs in culture. These results are consistent with previous reports about stress-induced hair loss (8, 17). However, these studies focused on apoptosis or proliferation of HFs in ex vivo. To further elucidate the mechanisms of stress-induced hair loss, researchers must investigate how CRF acts on cells that constitute the HFs, especially DPCs, which are specialized mesenchymal cells in HFs and are believed to play important roles in hair growth and the hair cycle. As a result, the expression of CRF receptors was identified in cultured human DPCs, which is the first in vitro report of this finding according to our knowledge. In addition, the expression of CRF receptors was elevated when CRF was added to cultured human DPCs. These findings suggested that the CRF receptors were highly sensitive.
To determine how CRF affects cultured human DPCs, we performed a cell proliferation assay. The results showed that CRF significantly changed the morphology (data not shown) and inhibited the increase in cell numbers of the cultured human DPCs. These data indicated that CRF inhibited proliferation or induced apoptosis. Therefore, to clarify the cause of the decreased cell viability, we stained the cultured human DPCs with Annexin V FITC and PI. However, there were no significant changes in apoptosis. Interestingly, the DNA contents of the cultured human DPCs were changed by CRF. The G2/M phase ratio was increased by CRF stimulation for up to 72 hours. In addition, ROS production was accelerated by CRF. Some reports have shown that ROS accumulation induces DNA damage, resulting in cell cycle arrest. Cellular senescence is a permanent cell cycle arrest induced by stress, including oxidative stress and DNA damage (29, 30). Other studies showed that premature cellular senescence caused by oxidative stress in DP compromised the interaction between the epithelium and DP cells, and the above phenomenon was observed mainly in androgenetic alopecia patients (31, 32). Although a further study on cell aging should be carried out, CRF leads to the production and accumulation of ROS in cells, thereby arresting cells in G2/M phase, which may ultimately lead to cell senescence.

CRF downregulated various cytokines, including HGF, Wnt5a, VEGF, and versican, which are known to be expressed in the anagen phase and regulate hair growth. Both the active form of HGF and VEGF are essential paracrine factors that promote hair growth (33, 34). Additionally, Wnts play an essential role in maintaining both hair inductive activity and anagen phase (35). Versican is related to the development of pathologic processes such as HF cycling and cancer (36). In addition, the mRNA and protein levels of TGFβ2 were increased with CRF treatment. TGFβ2 is an essential component of catagen induction in the human hair cycle (37). Overall, the growth inhibition of HFs and early catagen transition by CRF, a stress hormone, can be described as follows: CRF causes G2/M arrest by ROS production and accumulation, which can lead to human DPC aging. In addition, CRF reduces the expression of anagen-related cytokines and promotes catagen-related cytokines, allowing HFs to enter the regression phase.

When CRF is coupled to its receptors, adenylate cyclase and phospholipase C are activated, and cAMP is induced (38, 39). To confirm the initiation of CRF signals in human DPCs, we detected cAMP accumulation after CRF treatment. These data confirmed that CRF affects human DPCs through its receptors.

Previous studies have detected a local HPA axis in human HF (17, 18, 40). Fascinatingly, POMC, a precursor peptide of ACTH, was increased by CRF treatment at both the mRNA and protein levels. Since POMC expression was induced by CRF, further investigation is needed to clarify whether human DPCs have a functional local HPA axis. The levels of ACTH and cortisol were also increased when DPCs were stimulated by CRF. A complete local HPA axis might be present in cultured human DPCs (Fig. 6).

Interestingly, CRF receptors were confirmed to be expressed in the cultured ORS cells, and thus, the effects of CRF were investigated in these cells. The proliferation of ORS cells was not affected by CRF treatment (data not shown), while apoptotic responses have been reported in several in vivo studies (17). Because CRF induces premature catagen transition in hair organ culture, CRF stimulates human DPCs to secrete
ACTH or cortisol, and ACTH or cortisol in turn acts on the surrounding hair keratinocytes, including hair matrix cells and ORS cells, to initiate apoptotic reactions that lead to hair regression. Therefore, further research, such as coculture studies of ORS cells and DPCs, will be required for an improved understanding of the complex dynamics of HFs. Investigation of the mesenchymal-epithelial interaction within the HFs will address this issue.

Conclusions

In summary, this study showed that stress-induced hair loss can be explained through cellular senescence, such as the arrest of cell progression caused by ROS, and early catagen transition via modulation of hair cycle-related cytokines. Furthermore, these results suggest that a fully functional HPA axis exists in human DPCs and that CRF directly affects human DPCs as well as human HFs under stress conditions. Through in vitro studies using cells from HFs, this study helped improve our understanding of the mechanisms of stress hormones leading to hair growth inhibition and hair loss.

Methods

Human HF organ culture and hair cycle scoring

Human scalp skin specimens were obtained from dermatology patients after obtaining informed consent, following the Declaration of Helsinki principles. The study was approved by the Institutional Review Board of the CHA Bundang Medical Center (IRB No. CHAMC 2018-09-009).

Anagen human HFs were isolated by microdissection and maintained in William's E medium (WelGENE, South Korea) supplemented with 10 µg/ml insulin (Sigma-Aldrich, St. Louis, USA), 10 ng/ml hydrocortisone (Sigma-Aldrich), 20 mM HEPES (Invitrogen-Gibco-BRL, Grand Island, NY), and 1× antibiotic-antimycotic (Invitrogen-Gibco-BRL) for 1 day.

Isolated human HFs were exposed to 10^{-6} M CRF. On every second or third days, the medium was replaced, and human HFs were photodocumented. The hair cycle stages of cultured human HFs were scored every day according to the hair cycle scoring guidelines (41, 42).

Cell culture and treatment

Human DPC culture was established according to the method of Warren (43) with modifications. Cells were cultured in CnT Basal medium 2 containing two supplements (CnT-05.A and CnT-05.B) (CELLnTEC, Huissen, The Netherlands) with 1× antibiotic-antimycotic and incubated at 37 °C under 5% CO₂.

For human ORSC culture, HFs were isolated from the dermis and attached to dishes coated with collagen type I. Outgrowing ORSCs were cultured in Keratinocyte SFM (Invitrogen-Gibco-BRL) at 37 °C under 5% CO₂.
Cells were exposed to varying concentrations of CRF for up to 72 hours at 37 °C. Materials including receptor antagonists were added one hour before hormone treatments. Antalarmin (Sigma-Aldrich) and astressin 2-B (Sigma-Aldrich) were used as CRFR1- and CRFR2-specific antagonists, respectively.

Immunocytochemistry

Cells were fixed with 4% formaldehyde for 10 min, washed with PBS and blocked with 5% BSA in PBS for one hour. The slides were incubated with each primary antibody in blocking solution. After the cells were washed, they were labeled with secondary antibody with fluorescent dye for one hour. Then, the cells were immediately mounted with DAPI solution and visualized with fluorescence microscopy (Thermo Fisher Scientific, USA). The antibodies used in immunocytochemistry are listed in Table 1.

Cell proliferation

The changes in cell number were assessed using an EZ-Cytox assay kit (Daeil Lab Service, Korea) according to the manufacturer’s instructions. Human DPCs were seeded at a density of 7,000 cells per well in 48-well plates. After attachment, the cells were treated with each test material for 3 days. Medium was replaced with supplement-free CnT basal medium with 20 µl/well of EZ-Cytox solution. After 2 hours, the absorbance was measured at 450 nm using a Synergy H1 Multi-Mode Reader (Biotek, USA). The optical density (OD) of each well was used to calculate the cell number based on the authentic standard curves.

Measurement of intracellular reactive oxygen species (ROS)

Cells were washed with DPBS (WelGENE) and stained with 2',7'-dichlorodihydrofluorescein diacetate acetyl ester (H₂DCFDA, Thermo Fisher Scientific) for 30 min at 37 °C in dark conditions. Guava EasyCyte (Merck Millipore, Germany) was used for analysis.

Cell cycle analysis

Cells were washed with DPBS (WelGENE), fixed with 80% cold ethanol for 2 hours, centrifuged to remove the ethanol, and washed with cold DPBS 2 times. Cells were stained with PI/RNase in DPBS containing 1% FBS (HyClone, USA) for 30 min at 37 °C. Guava EasyCyte (Merck Millipore) was used to analyze the cell cycle.
**Apoptotic cell analysis**

CRF-exposed cells were analyzed using the FITC Annexin V Apoptosis Detection Kit (BD Biosciences, San Jose, CA) according to the manufacturer’s instructions. Annexin V is used to identify apoptotic cells, and PI is used to distinguish viable from nonviable cells. Guava EasyCyte (Merck Millipore) was used for analysis.

**Semiquantitative RT-PCR**

Total RNA was extracted from human DPCs using an RNA/protein one step kit (MACHEREY-NAGEL, Dueren, Germany) according to the manufacturer’s protocol. cDNA was synthesized from 2 µg of total RNA using reverse transcriptase, oligo dT and dNTPs and was used as the template for PCR. The cDNA was amplified in a PCR reaction containing 10 pM of specific primers using a Veriti 96 Well Thermal Cycler (Applied Biosystems, USA). Amplification consisted of 28~35 cycles as follows: denaturation at 95 °C for 5 min, annealing at 56.2~62 °C for 30 sec and a final extension at 72 °C for 5 min. The PCR products were separated by 2% agarose gel electrophoresis and visualized with a Gel Doc™ EX Imager (Bio-Rad, USA). All primers used are described in Table 2.

**Western blot analysis**

Total protein was extracted from human DPCs using an RNA/protein one step kit (MACHEREY-NAGEL) according to the manufacturer’s protocol. The proteins were separated by electrophoresis in 10% SDS-PAGE gels and transferred to 0.2 µm pore size PVDF membranes (Millipore, Bedford, MA, USA). The membranes were blocked with 5% skim milk in Tris buffered saline-Tween 20 (TBST 0.1% Tween 20) for an hour and then incubated with each primary antibody overnight at 4 °C. After three washes, the membranes were incubated with secondary antibody for one hour. After the samples were washed 5 times, immunoreactive protein was visualized with Clarity™ Western ECL Substrate (Bio-Rad) and detected using Amersham Hyperfilm™ ECL (GE Healthcare, UK). Experiments were performed three times. The antibodies used in the western blot analyses are listed in Table 1.

**cAMP assay**

Human DPCs were incubated (5 × 10^5 cells/100 mm dish) for 30 min at 37 °C in media containing 0.5 mM of phosphodiesterase inhibitor and 3-isobutyl-1-methylxanthine (IBMX) (Sigma-Aldrich). Then, CRF was added to media containing 0.5 mM of IBMX, and the cells were incubated for one hour at 37 °C. The cAMP concentration was measured in cultured human DPCs using a Cyclic AMP ELISA Kit (Cayman, Michigan, USA) according to the manufacturer’s protocol. A Synergy H1 Multi-Mode Reader (Biotek) was
used to measure the cAMP concentrations, and the concentration was calculated from the standard curve.

**ACTH assay**

Cells were seeded at a concentration of $3 \times 10^5$ cells per 100 mm dish. After attachment, the cells were treated with CRF receptor antagonists and then exposed to CRF. ACTH was measured with an ACTH ELISA kit (MD Bioproducts, Switzerland) according to the manufacturer’s protocol. The absorbance was measured with a Synergy H1 Multi-Mode Reader (Biotek). The OD of each well was used to calculate the ACTH concentration based on the authentic standard curves.

**Cortisol assay**

Cells were seeded at a concentration of $3 \times 10^5$ cells per 100 mm dish. Cells were pretreated with antalarmin and astressin 2-B for one hour. CRF was added to the media. Cells were collected and washed with cold PBS and then lysed with lysis buffer. Cortisol levels were measured in cultured human DPCs using a Parameter cortisol kit (R&D Systems, Minneapolis, MN) according to the manufacturer's protocol. The absorbance was measured using a Synergy H1 Multi-Mode Reader (Biotek). The OD of each well was used to calculate the cortisol concentration based on the values of the authentic standard curves.

**Statistical analysis**

Statistical analysis was performed using a two-tailed Student’s $t$-test to compare the experimental groups. $P$-values were considered to be significant at $P<0.05$ or $P<0.01$.

**Declarations**

**Ethics approval and consent to participate**

Human scalp skin specimens were obtained from dermatology patients after obtaining informed consent, following the Declaration of Helsinki principles. The study was approved by the Institutional Review Board of the CHA Bundang Medical Center (IRB No. CHAMC 2018-09-009).
Consent for publication

The publication has been approved by all authors.

Availability of data and materials

Not applicable

Competing interests

The authors declare that they have no competing interests

Funding

None

Authors' contributions

Eun Young Lee and You Jin Nam designed and performed the experiments equally. Sangjin Kang, Eun Ju Choi, Inbo Han, Jinwan Kim, Dong Hyun Kim, Ji Hae An, Sunghou Lee, Min Ho Lee and Ji Hyung Chung contributed reagents/materials/analysis tools. And all authors read and approved the final manuscript.

Acknowledgements

This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (Grant No. HN12C0053).

Abbreviations

CRF
corticotropin releasing factor
ACTH
adrenocorticotropic hormone
DPCs
dermal papilla cells
ROS
reactive oxygen species
POMC
proopiomelanocortin
HF
hair follicles
HPA axis
hypothalamic-pituitary-adrenal axis
CRFR
CRF receptor
GPCR
G protein coupled receptors
PKA
protein kinase A
CREB
cAMP response element binding protein
ORSC
outer root sheath cell
IBMX
3-isobutyl-1-methylxanthine

References

1. Paus R, Cotsarelis G. The biology of hair follicles. The New England journal of medicine. 1999;341(7):491-7.
2. Millar SE. Molecular mechanisms regulating hair follicle development. The Journal of investigative dermatology. 2002;118(2):216-25.
3. Stenn KS, Paus R. Controls of hair follicle cycling. Physiological reviews. 2001;81(1):449-94.
4. Yang CC, Cotsarelis G. Review of hair follicle dermal cells. Journal of dermatological science. 2010;57(1):2-11.
5. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. The New England journal of medicine. 1995;332(20):1351-62.
6. Arck PC, Slominski A, Theoharides TC, Peters EM, Paus R. Neuroimmunology of stress: skin takes center stage. The Journal of investigative dermatology. 2006;126(8):1697-704.
7. Zbytek B, Slominski AT. Corticotropin-releasing hormone induces keratinocyte differentiation in the adult human epidermis. Journal of cellular physiology. 2005;203(1):118-26.
8. Peters EM, Arck PC, Paus R. Hair growth inhibition by psychoemotional stress: a mouse model for neural mechanisms in hair growth control. Experimental dermatology. 2006;15(1):1-13.
9. Skobowiat C, Dowdy JC, Sayre RM, Tuckey RC, Slominski A. Cutaneous hypothalamic-pituitary-adrenal axis homolog: regulation by ultraviolet radiation. American journal of physiology Endocrinology and metabolism. 2011;301(3):E484-93.
10. Slominski AT, Zmijewski MA, Zbytek B, Tobin DJ, Theoharides TC, Rivier J. Key role of CRF in the skin stress response system. Endocrine reviews. 2013;34(6):827-84.

11. Miller DB, O’Callaghan JP. Neuroendocrine aspects of the response to stress. Metabolism: clinical and experimental. 2002;51(6 Suppl 1):5-10.

12. Hillhouse EW, Randeva H, Ladds G, Grammatopoulos D. Corticotropin-releasing hormone receptors. Biochemical Society transactions. 2002;30(4):428-32.

13. Perrin MH, Vale WW. Corticotropin releasing factor receptors and their ligand family. Annals of the New York Academy of Sciences. 1999;885:312-28.

14. Hauger RL, Risbrough V, Oakley RH, Olivares-Reyes JA, Dautzenberg FM. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Annals of the New York Academy of Sciences. 2009;1179:120-43.

15. Slominski A, Wortsman J, Pisarchik A, Zbytek B, Linton EA, Mazurkiewicz JE, et al. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2001;15(10):1678-93.

16. Ito N, Ito T, Betterman A, Paus R. The human hair bulb is a source and target of CRH. The Journal of investigative dermatology. 2004;122(1):235-7.

17. Ito N, Ito T, Kromminga A, Bettermann A, Takigawa M, Kees F, et al. Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2005;19(10):1332-4.

18. Slominski A, Wortsman J, Tuckey RC, Paus R. Differential expression of HPA axis homolog in the skin. Molecular and cellular endocrinology. 2007;265-266:143-9.

19. Wang L, Million M, Rivier J, Rivier C, Craft N, Stenzel-Poore MP, et al. CRF receptor antagonist astressin-B reverses and prevents alopecia in CRF over-expressing mice. PloS one. 2011;6(2):e16377.

20. Hadshiew IM, Foitzik K, Arck PC, Paus R. Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. The Journal of investigative dermatology. 2004;123(3):455-7.

21. Harrison S, Bergfeld W. Diffuse hair loss: its triggers and management. Cleveland Clinic journal of medicine. 2009;76(6):361-7.

22. Paus R, Arck P. Neuroendocrine perspectives in alopecia areata: does stress play a role? The Journal of investigative dermatology. 2009;129(6):1324-6.

23. Paus R, Langan EA, Vidali S, Ramot Y, Andersen B. Neuroendocrinology of the hair follicle: principles and clinical perspectives. Trends in molecular medicine. 2014;20(10):559-70.

24. Hunter HJ, Momen SE, Kleyn CE. The impact of psychosocial stress on healthy skin. Clinical and experimental dermatology. 2015;40(5):540-6.
25. Deng M, Li D, Zhang Y, Zhou G, Liu W, Cao Y, et al. Protective effect of crocin on ultraviolet B-induced dermal fibroblast photoaging. Molecular medicine reports. 2018;18(2):1439-46.

26. Botchkarev VA. Stress and the hair follicle: exploring the connections. The American journal of pathology. 2003;162(3):709-12.

27. Driskell RR, Clavel C, Rendl M, Watt FM. Hair follicle dermal papilla cells at a glance. Journal of cell science. 2011;124(Pt 8):1179-82.

28. Wang L, Guo LL, Wang LH, Zhang GX, Shang J, Murao K, et al. Oxidative stress and substance P mediate psychological stress-induced autophagy and delay of hair growth in mice. Archives of dermatological research. 2015;307(2):171-81.

29. Lu T, Finkel T. Free radicals and senescence. Experimental cell research. 2008;314(9):1918-22.

30. Nagano T, Yamao S, Terachi A, Yarimizu H, Itoh H, Katasho R, et al. D-amino acid oxidase promotes cellular senescence via the production of reactive oxygen species. Life science alliance. 2019;2(1).

31. Huang WY, Huang YC, Huang KS, Chan CC, Chiu HY, Tsai RY, et al. Stress-induced premature senescence of dermal papilla cells compromises hair follicle epithelial-mesenchymal interaction. Journal of dermatological science. 2017;86(2):114-22.

32. Upton JH, Hannen RF, Bahta AW, Farjo N, Farjo B, Philpott MP. Oxidative stress-associated senescence in dermal papilla cells of men with androgenetic alopecia. The Journal of investigative dermatology. 2015;135(5):1244-52.

33. Lee YR, Yamazaki M, Mitsui S, Tsuboi R, Ogawa H. Hepatocyte growth factor (HGF) activator expressed in hair follicles is involved in in vitro HGF-dependent hair follicle elongation. Journal of dermatological science. 2001;25(2):156-63.

34. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. The Journal of clinical investigation. 2001;107(4):409-17.

35. Kishimoto J, Burgeson RE, Morgan BA. Wnt signaling maintains the hair-inducing activity of the dermal papilla. Genes & development. 2000;14(10):1181-5.

36. Rahmani M, Wong BW, Ang L, Cheung CC, Carthy JM, Walinski H, et al. Versican: signaling to transcriptional control pathways. Canadian journal of physiology and pharmacology. 2006;84(1):77-92.

37. Soma T, Tsuji Y, Hibino T. Involvement of transforming growth factor-beta2 in catagen induction during the human hair cycle. The Journal of investigative dermatology. 2002;118(6):993-7.

38. Singh VK, Leu SJ. Corticotropin-releasing factor-induced production of cyclic AMP by human peripheral blood immunocytes. Immunology letters. 1993;35(3):239-45.

39. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiological reviews. 2000;80(3):979-1020.

40. Aguilera G. Corticotropin releasing hormone, receptor regulation and the stress response. Trends in endocrinology and metabolism: TEM. 1998;9(8):329-36.
41. Kligman AM. The human hair cycle. The Journal of investigative dermatology. 1959;33:307-16.

42. Peters EM, Hansen MG, Overall RW, Nakamura M, Pertile P, Klapp BF, et al. Control of human hair growth by neurotrophins: brain-derived neurotrophic factor inhibits hair shaft elongation, induces catagen, and stimulates follicular transforming growth factor beta2 expression. The Journal of investigative dermatology. 2005;124(4):675-85.

43. Warren R, Chestnut MH, Wong TK, Otte TE, Lammers KM, Meili ML. Improved method for the isolation and cultivation of human scalp dermal papilla cells. The Journal of investigative dermatology. 1992;98(5):693-9.

Tables

| Protein | Antibody company | Catalog number |
|---------|------------------|----------------|
| GAPDH   | Abfrontier       | LF-PA0018      |
| Wnt5a   | Abcam            | ab72583        |
| VEGF    | Abcam            | ab46154        |
| HGF     | Abcam            | ab83760        |
| TGFβ2   | Abcam            | ab36495        |
| Versican | Abcam        | ab19345        |
| ALP     | Abcam            | ab108337       |
| POMC    | Abcam            | ab32893        |
| CRF R1  | Abnova           | PAB7539        |
| CRF R2  | Abcam            | ab167379       |
| CRF R1/R2 | Santa Cruz Biotechnology | sc-1757 |
| CRF     | Abcam            | Ab8901         |

Table 1. Antibodies used for the immunocytochemistry and western blot
| Gene  | PCR primer sequence | Product size (bp) |
|-------|---------------------|------------------|
| Actin | F 5'- GCG TGA CAT TAA GGA GAA GC -3' | 174 |
|       | R 5'- AGG AAG GAA GCC TGG AAG A -3'  |    |
| Wnt5a | F 5'- CCA CAC AAG ACC TGG TCT ACA TC -3' | 172 |
|       | R 5'- GTC TGC ACG GTC TTG AAC TG -3'  |    |
| VEGF  | F 5'- TAC CTC CAC CAT GCC AAG T -3'  | 343 |
|       | R 5'- TGC ATT CAC ATT TGT TGT GC -3'  |    |
| HGF   | F 5'- TGC AGG ACA AAG AAG AAG -3'  | 378 |
|       | R 5'- GAA CTC CAG GGC TGA CAT TTG -3' |    |
| TGFβ2 | F 5'- AGG GTA CAA TGC CAA CTT CTG -3' | 144 |
|       | R 5'- GGT TCT AAA TCT TGG GAC ACG -3' |    |
| Versican | F 5'- TGA CTG TGG ATG GGG TTG TG -3' | 141 |
|       | R 5'- GCG TCA CAC TGC TCA AAT CC -3' |    |
| ALP   | F 5'- CCA AGG ACG CTG GGA AAT CT -3' | 172 |
|       | R 5'- TAT GCA TGA GCT GGT AGG CG -3' |    |
| POMC  | F 5'- CCC CTA CAG GAT GGA GCA CT -3' | 116 |
|       | R 5'- GGC GTT TTT GAA CAG CGT CA -3' |    |

**Table 2.** Primers used for the RT-PCR

---

**Figures**
Figure 1

Effect of CRF on human HF organ culture. Human HFs were incubated with or without CRF at 10-6 M for 10 days. (A) Hair shaft elongation was measured on days 0, 2, 5, and 10 using a stereomicroscope. The images were taken at 10× magnification. (B) Hair cycles of cultured human HFs were scored on day 0, 3 and 6 according to the hair cycle scoring guidelines. The images were taken at 50× magnification. p values of HF elongations compared with those of the control group on the same day, p-values were determined by t-tests, *: p<0.05, **: p<0.01
Figure 2

Response of cultured human DPCs to CRF. The endogenous expression of CRF and its receptors in cultured human DPCs (A) and ORSCs (B) (scale bars=50 µm, blue: DAPI, green: IgG, CRFR1, or CRFR1/2). (C) Human DPCs were exposed to 10-6 M CRF for 24 hours and assessed using immunocytochemistry (scale bars=100 µm, blue: DAPI, green: IgG, CRFR1, red: IgG, CRFR2) and (D) confirmed using western blots. (E), (F), (G) The bands were quantified using ImageJ. p values compared with the normal group by t-tests, *: p<0.05, **: p<0.01
Figure 3

The effects of CRF on the proliferation, apoptosis, and cell cycle of human DPCs. (A) Dose-dependent effect of CRF on the proliferation of human DPCs. Cells were exposed to CRF at concentrations of 10^-8 M, 10^-7 M, and 10^-6 M for 48 hours. (B) The protective effect of CRF antagonists on the proliferation of human DPCs. The cell number was determined using an EZ-Cytox kit. (C) The effect of CRF on apoptosis in DPCs. Samples were stained with Annexin V FITC and PI. (D) Cell cycle analysis of human DPCs at 24, 48, and 72 hours after CRF treatment using flow cytometry and (E) distribution of the cell cycle. (F) ROS generation after CRF treatment measured using H2DCFDA. CRF antagonists normalized the production of ROS on cultured human DPCs. Ant; antalarmin, A2B; astressin 2-B, C; CRF. p values compared with the normal group by t-test, ##: p<0.01. p values compared with the CRF treatment group by t-tests, *: p<0.05, **: p<0.01
Figure 4

The expression levels of anagen-related cytokines in cultured human DPCs with CRF treatment. Antagonists normalize the expression levels of anagen-related cytokines in cultured human DPCs with 10^-6 M CRF treatment. (A, B) mRNA expression levels (RT-PCR). The bands were quantified using ImageJ. (C, D) Protein expression levels (western blot). The bands were quantified using ImageJ. Ant; antalarmin, A2B; astressin 2-B, C; CRF. p values compared with the control group by t-tests, #: p<0.05, ##: p<0.01. p values compared with the CRF treatment group by t-tests, *: p<0.05, **: p<0.01
Figure 5

The local HPA axis in cultured human DPCs. (A) Human DPCs were exposed to 10^{-6} M CRF with antagonists for one hour, and the cAMP level was measured using an ELISA kit. p values compared with the control group by t-tests, #: p<0.05, ##: p<0.01. p values compared with the CRF treatment group by t-tests, *: p<0.05, **: p<0.01. (B) POMC mRNA levels with CRF treatment at 6 hours (RT-PCR). (C) POMC protein levels with CRF and antagonist treatment at 6 hours (western blot). (D) The bands were quantified using the ImageJ program. (E) ACTH concentrations at 24 hours. (F) Cortisol levels at 48 hours. Ant; antalarmin, A2B; astressin 2-B, C; CRF. p values compared with the control group by t-tests, #: p<0.05, ##: p<0.01. p values compared with the CRF treatment group by t-tests, *: p<0.05, **: p<0.01.
Figure 6

The possible mechanism of early catagen transition induced by the stress hormone CRF. DP; dermal papilla